Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to three newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, effective March 6, 2026.

The awards comprise non-statutory stock options for an aggregate of 60,175 shares and restricted stock units for 19,975 shares. Options carry a $10.27 exercise price, a ten-year term, and a four-year vesting schedule; RSUs vest over three years with the first installment on March 6, 2027.

News Market Reaction – OCUL

-0.70%

1 alert

-0.70% News Effect

On the day this news was published, OCUL declined 0.70%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement stock options: 60,175 shares Inducement RSUs: 19,975 shares Option exercise price: $10.27 per share +5 more

8 metrics

Inducement stock options 60,175 shares Aggregate non-statutory options for three new non-executive employees

Inducement RSUs 19,975 shares Aggregate restricted stock units for three new non-executive employees

Option exercise price $10.27 per share Equal to OCUL closing price on Nasdaq on March 6, 2026

Option term 10 years Non-statutory stock options granted under 2019 Inducement Plan

Option vesting cliff 25% after 1 year Initial vesting on first anniversary of grant date

Remaining option vesting Monthly over 3 years Equal monthly installments after first year, subject to service

RSU vesting period 3 years Equal annual installments starting March 6, 2027

New hires covered 3 employees Newly hired non-executive employees receiving inducement awards

Market Reality Check

Price: $9.50 Vol: Trading volume 5,602,625 ...

low vol

$9.50 Last Close

Volume Trading volume 5,602,625 vs 20-day average 9,336,977, indicating below-average activity ahead of this filing. low

Technical Shares at $10.27 are trading below the 200-day MA of $11.07, about 37.53% under the 52-week high and 77.07% above the 52-week low.

Peers on Argus

OCUL was down 0.58% while peers were mixed: BEAM +7.89%, LQDA +3.98%, TVTX +2.37...

OCUL was down 0.58% while peers were mixed: BEAM +7.89%, LQDA +3.98%, TVTX +2.37%, BLTE +1.01%, and TARS -0.92%, suggesting stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Investor conferences	Neutral	+6.5%	Multiple March investor conference appearances with webcast access for investors.
Feb 23	Clinical data update	Positive	+8.1%	Detailed SOL-1 Phase 3 data presentations and investor webcast scheduling.
Feb 17	Phase 3 results	Positive	-21.3%	SOL-1 Phase 3 trial met superiority endpoints with strong wet AMD outcomes.
Feb 13	Data timing update	Neutral	-21.3%	Announcement of upcoming SOL-1 topline data webcast and conference presentation.
Feb 06	Inducement grants	Neutral	+3.0%	Inducement equity awards to new hires under the 2019 Inducement Plan.

Pattern Detected

Recent major clinical milestones saw mixed reactions, with strong positive SOL-1 data coinciding with a sharp selloff, while conference and follow-up data events aligned with price gains.

Recent Company History

Over the past month, OCUL has issued several important updates. On Feb 17, 2026, positive SOL-1 Phase 3 superiority results for AXPAXLI in wet AMD prompted a -21.28% move, contrasting with the favorable data. Follow-up detailed SOL-1 data and investor events on Feb 23 and Feb 24 aligned with gains of 8.1% and 6.48%. Earlier, an inducement grant on Feb 6 coincided with a modest 2.95% rise, showing that routine equity grants have been relatively neutral catalysts compared with clinical milestones.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-30

OCUL has an effective Form S-3ASR shelf registration dated Sep 30, 2025, allowing it to offer various securities from time to time. The shelf is effective through Sep 30, 2028 with at least 1 recorded usage via a 424B5 prospectus supplement, providing flexibility for future capital-raising transactions.

Market Pulse Summary

This announcement details routine inducement equity awards—60,175 options and 19,975 RSUs—granted to...

Analysis

This announcement details routine inducement equity awards—60,175 options and 19,975 RSUs—granted to three new non-executive employees under the 2019 Inducement Plan, with standard multi-year vesting. Earlier in 2026, OCUL issued similar grants and reported major SOL-1 Phase 3 results, which have driven far larger stock moves. Investors tracking dilution and governance may monitor future equity awards and any use of the effective S-3ASR shelf alongside upcoming clinical and investor events.

Key Terms

nasdaq listing rule 5635(c)(4), non-statutory stock option, restricted stock unit, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"The awards were made as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statutory stock option financial

"consist of non-statutory stock option awards to purchase up to an aggregate of 60,175 shares"

A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.

restricted stock unit financial

"and restricted stock unit awards representing the right to receive an aggregate of 19,975 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vesting financial

"vests over four years, with 25% of the original number of shares vesting on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to three newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of March 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 60,175 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 19,975 shares of Ocular’s common stock. The stock option awards have an exercise price of $10.27 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments, with the first annual installment vesting on March 6, 2027, and subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

What inducement awards did Ocular Therapeutix (OCUL) grant on March 6, 2026?

They granted non-statutory stock options for 60,175 shares and RSUs for 19,975 shares. According to Ocular Therapeutix, awards were effective March 6, 2026 and issued under the 2019 Inducement Stock Incentive Plan to three new non-executive hires.

What is the exercise price and term for OCUL stock options granted March 6, 2026?

The options have a $10.27 exercise price and a ten-year term. According to Ocular Therapeutix, $10.27 equals the Nasdaq closing price on the effective grant date and each option expires ten years after grant.

How do the OCUL stock option vesting schedules work for the March 2026 grants?

Options vest 25% after one year then monthly over the next three years. According to Ocular Therapeutix, vesting is subject to continued service and the remaining 75% vests in equal monthly installments over years two through four.

When do the restricted stock units for OCUL granted March 6, 2026 begin to vest?

RSUs vest in three equal annual installments beginning March 6, 2027. According to Ocular Therapeutix, each RSU award vests annually over three years, subject to the recipient's continued service through each vesting date.

Under what plan were the inducement awards for OCUL issued and who received them?

Awards were issued under the 2019 Inducement Stock Incentive Plan to three newly hired non-executive employees. According to Ocular Therapeutix, the grants were made as inducements to accept employment and are governed by award agreements and plan terms.